A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Crenezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational
- Acronyms CREAD OLE
- Sponsors Roche
- 12 Feb 2019 This trial has been discontinued in Lithuania.
- 08 Feb 2019 This trial has been discontinued in Spain and Finland.
- 16 Oct 2018 Planned End Date changed from 7 Nov 2023 to 7 Nov 2022.